German stocks - Factors to watch on Dec. 20

Medigene AG

20/12/2018 05:54

BERLIN, Dec 20 (Reuters) - The following are some of the
factors that may move German stocks on Thursday:
    
    BAYER  BAYGn.DE 
    Novartis AG  NOVN.S  and Bayer are among nearly 30
drugmakers that have taken steps to raise the U.S. prices of
their medicines in January, ending a self-declared halt to
increases made by a pharma industry under pressure from the
Trump administration, according to documents seen by Reuters.
 urn:newsml:reuters.com:*:nL1N1YM0TL
    
    DEUTSCHE BOERSE  DB1Gn.DE 
    The U.S. swaps regulator on Thursday will give Deutsche
Boerse's Eurex the green light to clear interest rate swaps for
U.S. asset managers and hedge funds, allowing the company to
compete head-on with the London Stock Exchange and CME Group.
 urn:newsml:reuters.com:*:nL3N1YO636
    
    DEUTSCHE TELEKOM  DTEGn.DE 
    T-Mobile US Inc.  TMUS.O  is delaying the debut of its
much-anticipated video service after the project proved more
complex than expected, Bloomberg reported, citing people
familiar with the situation.  urn:newsml:reuters.com:*:nL3N1YO563
    
    LINDE  LINI.DE 
    A Munich court is expected to rule in an investor suit
against Linde AG over the fact that the company's shareholders
were not able to vote on a merger with Praxair at its annual
general meeting.
        
    HELLOFRESH  HFGG.DE 
    The group said it concluded a three-year 80 million euro
revolving credit facility.  urn:newsml:reuters.com:*:nFWN1YO0Z7
    
    HOCHTIEF  HOTG.DE 
    Australian unit Cimic  CIM.AX  said its units won a A$184
million ($130.47 million) coal processing plant contract.
 urn:newsml:reuters.com:*:nFWN1YO13W
    Separately, Cimic's contractors were selected to build Stage
1 of the Parramatta Light Rail project in a 50-50 joint venture
with Downer, generating revenue to CPB Contractors of A$420
million.  urn:newsml:reuters.com:*:nFWN1YO0X3
    
    MEDIGENE  MDG1k.DE 
    Medigene said its dendritic cell (DC) vaccine was well
tolerated by patients in a Phase I/II clinical trial with 20
patients with acute myeloid leukemia, with no serious adverse
events (SAEs) related to the treatment.  urn:newsml:reuters.com:*:nFWN1YO0W9
    
    HORNBACH HOLDING  HBH.DE  
    Q3 results due. 

    OVERSEAS STOCK MARKETS  
    Dow Jones  .DJI  -1.5 pct, S&P 500 .SPX  -1.5 pct, Nasdaq
 .IXIC  -2.2 pct at close.  .N 
    Nikkei  .N225  -3.3 pct, Shanghai stocks  .SSEC  -1.2 pct.
 .T   .SS 
    Time: 5:53 GMT. 

    GERMAN ECONOMIC DATA
    No economic data scheduled.
    
    EUROPEAN FACTORS TO WATCH  WATCH/EU 
    DIARIES  DE/DIA   WEU/EQUITY 
    REUTERS TOP NEWS  TOP/NEWS 


($1 = 1.4102 Australian dollars)

 (Reporting by Berlin Speed Desk)
 ((frankfurt.newsroom@thomsonreuters.com; +49 30 2888 5169))